Revcovi for Adenosine Deaminase Severe Combined Immune Deficiency

February 13, 2019

Revcovi

Revcovi (elapegademase-lvlr, Lediant Biosciences)

Indications: Adenosine deaminase severe combined immune deficiency (ADA-SCID)

Dosage:

  • Starting: 0.4 mg/kg (idea body weight) in 2 intramuscular supplements (0.2 mg/kg twice per week)

  • Maintenance dosing: increments of 0.033 mg/kg weekly if...
  • trough ADA activity is under 30 mmol/hr/L

  • trough deoxyadenosine nucleotides (dAXP) are above 0.02 mmol/L

  • the immune reconstitution is inadequate based on the clinical assessment of the patient

Contraindications: N/A

Click here for more prescribing information